Indaptus reports Q3 2026 results, points to sleep-tech device and completed $24 million raise
Indaptus says it will use proceeds from a September private placement toward early research on a neurotechnology device for sleep conditions, while Decoy20 clinical spending has wound down.
Indaptus Therapeutics reported financial results for the third quarter and first nine months of 2026 on November 13, 2026, alongside a corporate update. Chief Executive Officer and Chairman Junyi Dai said the company aims to position Indaptus for its next phase of growth by pursuing opportunities with long-term potential, and said the completed $24.0 million private placement gives the company financial resources and strategic flexibility.1
The company said it is exploring a neurotechnology- and neural-network-based device aimed at certain sleep-related conditions, with early-stage research and preclinical evaluation intended to assess scientific potential and a possible path toward an eventual FDA submission.1 The underlying private placement, for 20,338,974 shares of common stock, was entered into on September 8, 2026, for gross proceeds of about $24.0 million; it closed on October 16, 2026, with roughly $20.5 million received by September 30 and the remaining $3.5 million received in October.1
On the pipeline side, R&D spending fell sharply: third-quarter R&D expenses dropped 82% to about $0.3 million versus $1.5 million a year earlier, and nine-month R&D expenses fell 83% to about $1.1 million versus $6.5 million in 2025.1 The company attributed the decline mainly to reduced clinical costs tied to the Decoy20 Phase 1 study, along with lower payroll costs following headcount and salary reductions.1
On liquidity, Indaptus held about $26.6 million in cash and cash equivalents plus $4.0 million in short-term investments, in the form of on-demand certificates of deposit, as of September 30, 2026.1 Management said these resources, based on its current operating plan, are sufficient to fund anticipated operating expenses, capital expenditures, and planned R&D activities.1 Net loss for the first nine months of 2026 was about $5.4 million, down from $12.7 million in the same period of 2025.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.